Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)Joanneke K Overbeek, Niels A D Guchelaar, Ma Ida Mohmaed Ali, et al.
Cancers|December 24, 2021
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate CancerEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Targeted Oncology|June 18, 2024
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab GovitecanDirk J A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, et al.
Contemporary Clinical Trials Communications|April 18, 2025
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)Joanneke K Overbeek, Niels A D Guchelaar, Ma Ida Mohmaed Ali, et al.
Targeted Oncology|September 28, 2018
Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and ExemestaneAnnelieke E C A B Willemsen, Lioe-Fee de Geus-Oei, Maaike de Boer, et al.
The Oncologist|September 19, 2025
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinomaJorien B E Janssen, Kirti K Iyer, Sophie L Gerritse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2022
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter studyS L Groenland, R A G van Eerden, K Westerdijk, et al.
ESMO Open|June 4, 2024
Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomesE L Giraud, K Westerdijk, M B A van der Kleij, et al.
Clinical Pharmacokinetics|July 16, 2024
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma CohortMarinda Meertens, Eline L Giraud, Maud B A van der Kleij, et al.
British Journal of Cancer|July 6, 2024
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective studyMaud B A van der Kleij, Niels A D Guchelaar, Marinda Meertens, et al.
Pageof 13